ATE132532T1 - Expression von tetanustoxinfragment c - Google Patents

Expression von tetanustoxinfragment c

Info

Publication number
ATE132532T1
ATE132532T1 AT90909052T AT90909052T ATE132532T1 AT E132532 T1 ATE132532 T1 AT E132532T1 AT 90909052 T AT90909052 T AT 90909052T AT 90909052 T AT90909052 T AT 90909052T AT E132532 T1 ATE132532 T1 AT E132532T1
Authority
AT
Austria
Prior art keywords
fragment
expression
tetanustoxin
tetanus toxin
mature fragment
Prior art date
Application number
AT90909052T
Other languages
English (en)
Inventor
Neil Fraser Fairweather
Andrew Joseph Makoff
Original Assignee
Evans Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evans Medical Ltd filed Critical Evans Medical Ltd
Application granted granted Critical
Publication of ATE132532T1 publication Critical patent/ATE132532T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90909052T 1989-06-20 1990-06-20 Expression von tetanustoxinfragment c ATE132532T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898914122A GB8914122D0 (en) 1989-06-20 1989-06-20 Polypeptide expression

Publications (1)

Publication Number Publication Date
ATE132532T1 true ATE132532T1 (de) 1996-01-15

Family

ID=10658724

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90909052T ATE132532T1 (de) 1989-06-20 1990-06-20 Expression von tetanustoxinfragment c

Country Status (9)

Country Link
US (1) US5443966A (de)
EP (1) EP0478602B1 (de)
JP (1) JP2981286B2 (de)
AT (1) ATE132532T1 (de)
DE (1) DE69024652T2 (de)
DK (1) DK0478602T3 (de)
ES (1) ES2084030T3 (de)
GB (1) GB8914122D0 (de)
WO (1) WO1990015871A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601826A (en) * 1989-06-30 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Peptide which produces protective immunity against tetanus
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
AU4545393A (en) * 1992-06-30 1994-01-24 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Peptide which produces protective immunity against tetanus
ATE174628T1 (de) 1992-07-31 1999-01-15 Medeva Holdings Bv Expression rekombinanter fusionsproteine in attenuierten bakterien
GB9401787D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
WO1997026277A2 (en) * 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
WO1997035612A1 (fr) * 1996-03-23 1997-10-02 The Research Foundation For Microbial Diseases Of Osaka University Antigene a fragment fonctionnel de la toxine du tetanos, et vaccin contre le tetanos
US5958469A (en) * 1997-05-14 1999-09-28 Eastman Kodak Company Method for fabricating tools for molding diffractive surfaces on optical lenses
ES2281135T3 (es) * 1997-08-14 2007-09-16 Institut Pasteur Proteinas hibridas de un toxoide tetanico que migran de forma retrograda y transinaptica al snc.
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
CZ20024224A3 (cs) 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2004024067A2 (en) * 2002-09-10 2004-03-25 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
EP1638601B1 (de) * 2003-06-23 2008-11-19 Baxter International Inc. Trägerproteine für impfstoffe
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses
EP1790358A1 (de) * 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Proteinkonstrukte designed zum Targeting und Lyse von Zellen
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
WO2011143557A2 (en) 2010-05-14 2011-11-17 The Children's Hospital Of Philadelphia Humanized ttc and methods of use thereof
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2014135651A1 (en) 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
WO2016001762A1 (en) 2014-07-02 2016-01-07 Spherium Biomed S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2355094C3 (de) * 1973-11-03 1979-05-23 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Tetanus-Impfstoffs
GB8516442D0 (en) * 1985-06-28 1985-07-31 Wellcome Found Cloned antigen

Also Published As

Publication number Publication date
JP2981286B2 (ja) 1999-11-22
GB8914122D0 (en) 1989-08-09
DE69024652T2 (de) 1996-05-15
WO1990015871A1 (en) 1990-12-27
JPH04506005A (ja) 1992-10-22
ES2084030T3 (es) 1996-05-01
EP0478602B1 (de) 1996-01-03
EP0478602A1 (de) 1992-04-08
DE69024652D1 (de) 1996-02-15
DK0478602T3 (da) 1996-02-05
US5443966A (en) 1995-08-22

Similar Documents

Publication Publication Date Title
ATE132532T1 (de) Expression von tetanustoxinfragment c
ES8306797A1 (es) Un metodo para producir un polipeptido.
ATE195347T1 (de) Methoden der erhöhung der sekretion von überexpremierten proteinen
ATE188508T1 (de) Impfstoffe gegen diphtherietoxin
DE69002817D1 (de) Vakzine.
YU47525B (sh) Zeleno staklo za apsorpciju infracrvenog i ultravioletnog zračenja i automobilsko staklo izradjeno od istog
DK0575443T3 (da) Ærteproteinhydrolysat, fremgangsmåde til dets fremstilling og anvendelse deraf
NO961812D0 (no) Humanproteaseinhibitorer av Kunitz-type
ATE41034T1 (de) Herstellung von protein a.
FI952148L (fi) Geenitekninen menetelmä ja isäntä ksylitolin valmistamiseksi
ATE162311T1 (de) Immunoassay zum nachweis von kollagen oder kollagenfragmenten
JPS57134465A (en) Manufacture of 1,5-didesoxy-1,5-imino-d- glucitol or n-derivative thereof
ES547436A0 (es) Un procedimiento para producir un adn complementario clonadoo su adn modificado que codifica un polipeptido de factor denecrosis de tumores
BG41125A3 (en) Method for preparing benzamides
ATE81136T1 (de) Immunogenes produkt, erhalten durch expression in einer rekombinanten hefe, und verfahren zu seiner reinigung.
ES8704975A1 (es) Un procedimiento para preparar un polipeptido que se puede utilizar en una vacuna para proteger seres humanos contra infeccion por plasmodium falciparum
ATE194624T1 (de) Mutanten von menschlichem antithrombin iii
NO913078L (no) Oekt proteinproduksjon i dyr.
ES2023560A6 (es) Procedimiento para la produccion de hidrato de cefradina y solvato de cefradina y dimetilformamida.
ATE106744T1 (de) Neue methode zur induzierung der ovulation beim menschen.
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
DK0456986T3 (da) Varmeresistent beta-galactosyltransferase, fremtillingsfremgangsmåde herfor og anvendelse heraf
ATE126794T1 (de) Verfahren zur herstellung von formyltetrahydropyranen.
DE69004199D1 (de) Herstellung von Cymenol durch direkte Dehydrogenierung.
NO843750L (no) Immuninterferon og fremgangsmaate ved fremstilling derav

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time